IGM Biosciences, Inc.
325 East Middlefield Road
Mountain View
CA
94043
United States
Tel: (650) 965-7873
Website: https://igmbio.com/
Email: info@igmbio.com
About IGM Biosciences, Inc.
IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. IgM antibodies have inherent properties that we believe may enable them to improve upon the efficacy and safety of IgG antibodies in multiple therapeutic applications. We have created a proprietary IgM antibody technology platform that we believe is particularly well suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Our lead product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3, and we plan to initiate a Phase 1 clinical trial for the treatment of relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL) patients in 2019. Our second product candidate is expected to be an IgM antibody targeting Death Receptor 5 (DR5).
22 articles with IGM Biosciences, Inc.
-
IGM Biosciences Announces Expansion of IgM Platform into Infectious Diseases, Publication of Preclinical Data in Nature Demonstrating Engineered IgM Antibody Antiviral Activity for the Treatment and Prevention of COVID-19
6/3/2021
IGM Biosciences Announces Expansion of IgM Platform into Infectious Diseases, Publication of Preclinical Data in Nature Demonstrating Engineered IgM Antibody Antiviral Activity for the Treatment and Prevention of COVID-19
-
IGM Biosciences to Present at the Jefferies Virtual Healthcare Conference - May 26, 2021
5/26/2021
IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021 at 1:00 p.m. EDT.
-
BioSpace Movers & Shakers, April 16
4/16/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
IGM Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/7/2021
IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, announced that Fred Schwarzer, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 11:40 a.m. ET.
-
IGM Announces Pricing of Upsized $200 million Public Offering
12/9/2020
IGM Biosciences, Inc. announced the pricing of its upsized underwritten public offering of shares of its common stock at a price to the public of $90.00 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase shares of its common stock at a purchase price of $89.99 per each pre-funded warrant, which represents the per share public offering price of common stock less the $0.01 per share exercise price for each such pre-funded warrant.
-
IGM Biosciences Presents First Clinical Data from IGM-2323 in Non-Hodgkin’s Lymphoma at 2020 ASH Annual Meeting
12/5/2020
9 of 14 Patients Showed Reduction in Tumor Size, Including Two Recently Reported Complete Responses
-
IGM Biosciences to Present at Three Upcoming Investor Conferences - Nov 09, 2020
11/9/2020
IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, announced that Fred Schwarzer, Chief Executive Officer, will present at three upcoming investor conferences:
-
IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-8444 for the Treatment of Solid Cancers and Non-Hodgkin’s Lymphoma
9/30/2020
IGM Biosciences, Inc. announced that the first patient has been dosed in its Phase 1 clinical trial evaluating IGM-8444, an IgM antibody targeting the Death Receptor 5 protein, in patients with solid cancers and non-Hodgkin’s lymphoma.
-
IGM Biosciences to Present at Four Upcoming Investor Conferences - Sep 02, 2020
9/2/2020
IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, announced that Fred Schwarzer, Chief Executive Officer, will present at four upcoming investor conferences
-
IGM Biosciences to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
8/4/2020
IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, announced that Fred Schwarzer, Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11 at 1:45 p.m. ET.
-
IGM Biosciences to Present at the Jefferies 2020 Healthcare Conference
5/28/2020
IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, announced that Fred Schwarzer, Chief Executive Officer, will present at the Jefferies 2020 Healthcare Conference on Thursday, June 4 at 10:00 a.m. ET.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 30, 2020.
-
Atreca, BeiGene, and IGM Biosciences Agree to Collaborate on Novel Antibody Treatment for COVID-19
4/29/2020
Companies to utilize proprietary platforms to discover, develop, and manufacture potential therapeutic antibodies to combat ongoing COVID-19 pandemic
-
IGM Biosciences to Announce Fourth Quarter and Year-end 2019 Financial Results and Host Conference Call and Webcast on March 26, 2020
3/19/2020
IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, announced that it will report its fourth quarter and year-end 2019 financial results on Thursday, March 26, 2020.
-
IGM Biosciences to Present at Two Upcoming Investor Conferences in March 2020
3/4/2020
IGM Biosciences, Inc. announced that members of the management team will present at two upcoming investor conferences
-
IGM Biosciences Appoints Eric Humke, M.D., Ph.D., as Vice President, Clinical Development, Apoptosis
1/7/2020
IGM Biosciences, Inc. announced the appointment of Eric Humke, M.D., Ph.D., to the newly created position of Vice President, Clinical Development, Apoptosis.
-
IGM Biosciences to Present at Three Upcoming Investor Conferences in November and December 2019
11/12/2019
IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients, announced that Fred Schwarzer, Chief Executive Officer, will present at three upcoming investor conferences
-
IGM Biosciences Announces Third Quarter 2019 Financial Results
11/7/2019
IGM Biosciences, Inc. announced its financial results for the third quarter ended September 30, 2019 and provided an update on recent developments.
-
IGM Biosciences Appoints Julie Hambleton, M.D., to Board of Directors
8/15/2018
GM Bioscences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointment of Julie Hambleton, M.D., to its Board of Directors.
-
Biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those adjustments.